Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 161Recurrence 30Neoplasms, Plasma Cell 11Neoplasms 7Lymphoma, Mantle-Cell 7Paraproteinemias 6Lymphoma, Follicular 5Hematologic Neoplasms 5Lymphoma, Non-Hodgkin 4Immunoglobulin Light-chain Amyloidosis 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Immunoproliferative Disorders 3Immune System Diseases 3Hematologic Diseases 3Carcinoma, Non-Small-Cell Lung 3Blood Protein Disorders 3Plasmacytoma 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Hemostatic Disorders 2Hemorrhagic Disorders 2Bone Marrow Neoplasms 2Amyloidosis 2Wilms Tumor 1

Interventions

TH 302 4Bacterial Load 2pomalidomide 1fluoromisonidazole 1Tirapazamine 1Ipilimumab 1Ethiodized Oil 1Dexamethasone 1Bortezomib 1AQ4N 13-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hypoxia × Bortezomib × Clear all
NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Threshold Pharmaceuticals

Phase 1/2 Unknown
98 enrolled
Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡